Join the club for FREE to access the whole archive and other member benefits.

Oisin Biotechnologies

Drug development company focused on the senolytic technology to fight age-related diseases

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Visit website: https://www.oisinbio.com/

 oisin-biotechnologies

Details last updated 04-May-2019

Oisin Biotechnologies News

Reason reports back from Rejuvenation Startup Summit 2024

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials

Longevity Technology interviews Aubrey de Grey about senolytics and other senotherapeutics

Longevity Technology interviews Aubrey de Grey about senolytics and other senotherapeutics

Longevity Technology - 05-Aug-2021

Most approaches have their limitations but good progress is being made on several fronts

Oisín raised $9.5M to advance senolytic therapies for kidney & age-related diseases

Oisín raised $9.5M to advance senolytic therapies for kidney & age-related diseases

Longevity Technology - 28-May-2021

Investigational therapy on old mice cleared senescent cells up to 70%, extending life by 20%

LMC provides background and success outlook on 14 leading senolytic companies

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...


Display all news

Oisin Biotechnologies is also referenced in the following:

Body-wide Gene Therapy with Proteo-Lipid Vehicles - Matthew Scholz at Longevity Summit Dublin 2024

Matthew Scholz delivered a keynote on body-wide gene therapy using proteo-lipid vehicles

SENS Annual Report 2020

Quick summary of SENS’ latest research projects and other activities

People at Oisin Biotechnologies

Gary Hudson

Executive Chairman and co-founder of Oisín Biotechnologies

Matthew Scholz

Founder and Chief Executive Officer at Oisín Biotechnologies

John Lewis

CSO Oision Biotechnologies, co-founder of Oisin Oncology and Chair in Prostate Cancer Research at the University of Alberta

Topics mentioned on this page:
Senescent Cells